Swallowing a company that's half its size is no small feat for even the most cash-rich companies. Schering-Plough
The company announced that it will sell common stock and convertible preferred stock to raise more than $4 billion. The rest of the funds will come from debt and existing cash.
Unlike Mylan Laboratories
The addition of Organon BioSciences will add about $5 billion in annual sales to Schering's revenues. Most importantly, the expanded sales will help Schering rely less on its cholesterol drugs Zetia, as well as Vytorin, which combines Zetia and Merck's
In addition to the existing products, Schering also inherits an extensive pipeline including five drugs in late stage clinical trials. The drugs cover a gamut of diseases from schizophrenia to infertility to insomnia. It also inherits a healthy pipeline including six phase 2 drugs and 10 drugs in phase 1 trials.
Schering is going to need to take some serious cost-cutting measures after the merger to justify the high acquisition price. One place it will probably be able to cut margins is in combining the two companies' animal health divisions. The resulting division will be larger than that of rival Pfizer
The acquisition is expected to close by the end of the year, so it will take a while before investors know whether Schering's major acquisition has paid off. Funding part of the acquisition through a stock offering will decrease future interest payments and is an especially good idea with the stock, as potentially overvalued as it is. If Schering can use the same tactics it used to produce 11 quarters in a row of adjusted double-digit sales growth to its new acquisition, its share price should continue to fetch the high P/E ratio it now sports.